lab test tubes blue via Bigstock
May 15, 2017| BiomX Ltd., an Israeli microbiome therapeutics company, announced today that it has raised $24 million in a Series A funding round. The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC, Inc. and Takeda Ventures, Inc. with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors. BiomX, previously named MBcure, was founded in the FutuRx Ltd. incubator, with the support of the Israel Innovation Authority.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

New Israeli Breakthrough In Understanding Onset Of Alzheimer’s
October 03, 2023

Israeli Pineapple-Based Burn Therapy Treating Injured US Troops
October 02, 2023

AI Can Predict Future Heart Attacks By Analyzing CT Scans
October 01, 2023

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023
Facebook comments